Shikonin sensitises osimertinib-resistant lung adenocarcinoma to ferroptosis through HES1-mediated ATF3 upregulation

Read full text Summarise with VIRAT
Authors: Haiwen Li, Quan Yang, LI Yang, Xiaobi Huang, Yongyang Chen, Yonghua Chen, Yuexin Zheng, Xiao Lei, Miao Yin, Yuetong Jiang, Yudong Guo, Yanfeng Liang
+4 more Qihe Long, Zhixiong Yang, Lili Yu, Wenmei Su
Cited by: 0
References: 50

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Acquired resistance to osimertinib poses a major challenge in treating EGFR-mutant lung adenocarcinoma (LUAD). Here, we demonstrate that shikonin, a natural compound from Lithospermum erythrorhizon, synergizes with osimertinib to overcome this resistance by inducing ferroptosis. In osimertinib-resistant LUAD cells (PC9-OR/H1975-OR), the shikonin-osimertinib combination significantly enhances cytotoxicity and suppresses proliferation while triggering ferroptotic events, including reactive oxygen species accumulation, lipid peroxidation, and iron overload alongside glutathione depletion. RNA-sequencing identifies Hes family BHLH transcription factor 1 (HES1) downregulation as crucial to this process. HES1 knockdown replicates the combination’s effects, confirming its key role. Mechanistically, ATF3 is identified as a direct transcriptional target of HES1, with HES1 binding to the ATF3 promoter (-786 to -779 nt) to repress its transcription. The shikonin-osimertinib combination relieves this repression, leading to ATF3-mediated suppression of the ferroptosis regulators SLC7A11 and GPX4. In vivo, this combination potently inhibits tumor growth in xenograft models without observable toxicity. Our study reveals a novel HES1/ATF3 axis governing ferroptosis and proposes shikonin as a promising therapeutic adjuvant to overcome osimertinib resistance in LUAD.

Fields of Study & Subjects

Ferroptosis and cancer prognosis Lung Cancer Treatments and Mutations Ferrocene Chemistry and Applications

Publication details

Journal / source
Acta Biochimica et Biophysica Sinica
Publication date
27 March 2026
Language
EN